Compare DSL & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | TNDM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | DSL | TNDM |
|---|---|---|
| Price | $11.49 | $27.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $26.95 |
| AVG Volume (30 Days) | 600.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 11.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $10.96 |
| Revenue Next Year | N/A | $9.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $10.58 | $10.00 |
| 52 Week High | $12.91 | $34.99 |
| Indicator | DSL | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 80.63 |
| Support Level | $11.10 | $19.48 |
| Resistance Level | $11.41 | N/A |
| Average True Range (ATR) | 0.07 | 1.70 |
| MACD | -0.01 | 1.12 |
| Stochastic Oscillator | 3.39 | 94.47 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.